MREO Valuation

Mereo BioPharma Group PLC

Add to Watchlist

Advanced Chart

1.760

-0.04(-2.222%)1D

MREO Relative Valuation

MREO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MREO is overvalued; if below, it's undervalued.

Historical Valuation

Mereo BioPharma Group PLC (MREO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.80 is considered Undervalued compared with the five-year average of -81.69. The fair price of Mereo BioPharma Group PLC (MREO) is between 7.93 to 17.77 according to relative valuation methord. Compared to the current price of 1.79 USD , Mereo BioPharma Group PLC is Undervalued By 77.36%.

Relative Value

Fair Zone

7.93-17.77

Current Price：1.79

77.36%

Undervalued

-86.75

Trailing

Forward

9.58

EV/EBITDA

Mereo BioPharma Group PLC. (MREO) has a current EV/EBITDA of 9.58. The 5-year average EV/EBITDA is -1.42. The thresholds are as follows: Strongly Undervalued below -13.61, Undervalued between -13.61 and -7.51, Fairly Valued between 4.67 and -7.51, Overvalued between 4.67 and 10.76, and Strongly Overvalued above 10.76. The current Forward EV/EBITDA of 9.58 falls within the Overvalued range.

-6.87

EV/EBIT

Mereo BioPharma Group PLC. (MREO) has a current EV/EBIT of -6.87. The 5-year average EV/EBIT is -4.76. The thresholds are as follows: Strongly Undervalued below -12.20, Undervalued between -12.20 and -8.48, Fairly Valued between -1.05 and -8.48, Overvalued between -1.05 and 2.67, and Strongly Overvalued above 2.67. The current Forward EV/EBIT of -6.87 falls within the Historic Trend Line -Fairly Valued range.

1.80

Mereo BioPharma Group PLC. (MREO) has a current PS of 1.80. The 5-year average PS is 9.28. The thresholds are as follows: Strongly Undervalued below -9.83, Undervalued between -9.83 and -0.28, Fairly Valued between 18.83 and -0.28, Overvalued between 18.83 and 28.38, and Strongly Overvalued above 28.38. The current Forward PS of 1.80 falls within the Historic Trend Line -Fairly Valued range.

7.16

P/OCF

Mereo BioPharma Group PLC. (MREO) has a current P/OCF of 7.16. The 5-year average P/OCF is -8.34. The thresholds are as follows: Strongly Undervalued below -72.27, Undervalued between -72.27 and -40.31, Fairly Valued between 23.63 and -40.31, Overvalued between 23.63 and 55.60, and Strongly Overvalued above 55.60. The current Forward P/OCF of 7.16 falls within the Historic Trend Line -Fairly Valued range.

2.70

P/FCF

Mereo BioPharma Group PLC. (MREO) has a current P/FCF of 2.70. The 5-year average P/FCF is -9.75. The thresholds are as follows: Strongly Undervalued below -47.19, Undervalued between -47.19 and -28.47, Fairly Valued between 8.97 and -28.47, Overvalued between 8.97 and 27.69, and Strongly Overvalued above 27.69. The current Forward P/FCF of 2.70 falls within the Historic Trend Line -Fairly Valued range.

Mereo BioPharma Group PLC (MREO) has a current Price-to-Book (P/B) ratio of 5.28. Compared to its 3-year average P/B ratio of 5.78 , the current P/B ratio is approximately -8.63% higher. Relative to its 5-year average P/B ratio of 3.23, the current P/B ratio is about 63.42% higher. Mereo BioPharma Group PLC (MREO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -16.89%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -16.38% , the current FCF yield is about -100.00% lower.

5.28

P/B

Median3y

5.78

Median5y

3.23

-10.90

FCF Yield

Median3y

-16.89

Median5y

-16.38

Competitors Valuation Multiple

The average P/S ratio for MREO's competitors is 6.18, providing a benchmark for relative valuation. Mereo BioPharma Group PLC Corp (MREO) exhibits a P/S ratio of 1.80, which is -70.89% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MREO.O

Mereo BioPharma Group PLC

Kyverna Therapeutics Inc

6.95

306.42M

ALDX.O

Aldeyra Therapeutics Inc

4.81

289.38M

CADL.O

Candel Therapeutics Inc

Performance Decomposition

Market capitalization of MREO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of MREO in the past 1 year is driven by Unknown.